AnthroTronix and Nview Health Collaboration Powers Seamless Assessment of Cognition and Behavioral Health

AnthroTronix and Nview Health Collaboration Powers Seamless Assessment of Cognition and Behavioral Health — Provides Consistent Measurement of Cognitive and Behavioral Health in One Place — SILVER SPRING, Md. – AnthroTronix and Nview Health announced today they have partnered to combine two technologies to test both a person’s cognitive function and their behavioral health. Used together, these technologies can provide healthcare practitioners with better insight into a person’s complete behavioral health and wellness. AnthroTronix’s DANA TM is an FDA cleared clinical neurocognitive assessment tool that uses a smartphone or tablet to measure and monitor changes in a person’s brain/cognitive function. The app can help clinicians track cognitive function for conditions such as depression, dementia/Alzheimer’s Disease, and Post-Traumatic Stress Disorder. “Cognitive function and behavioral health are closely linked,” said AnthroTronix CEO Cori Lathan. “Our behavioral health status effects our cognitive efficiency so to get a clear picture of a person’s brain health, it’s important to test both. Our partnership with Nview Health now enables healthcare providers the ability to do that.” Nview’s diagnostic instrument, the M.I.N.I. — Mini International Neuropsychiatric Interview — is a short, structured diagnostic interview designed to evaluate the most common DSM-5 and ICD-10 psychiatric disorders. It enables healthcare professionals to rapidly deliver a behavioral health diagnosis and has been used in patient care and clinical research for more than 25 years. “Our partnership with AnthroTronix now allows us to measure an individual’s cognitive status, which is essential to the care and treatment of behavioral health disorders,” said Nview Health Chief Executive Officer and Co-Founder Thomas R. Young, M.D. ### About AnthroTronix AnthroTronix, an engineering research and development company, produces human-centered technologies that advance health, communication, education, and defense. We...

Health-eBrain Study to Launch Phase II

Health-eBrain Study to Launch Phase II Mobile Platform Captures and Analyzes Cognitive and Emotional Health of Caregivers of Alzheimer’s Patients Toronto – BrightFocus Foundation, Geoffrey Beene Foundation Alzheimer’s Initiative, AnthroTronix, and Mindoula, have launched Phase II of the Health-eBrain Study, investigating the impact the Alzheimer’s caregiving experience has on brain and behavioral health. The announcement will be made at the Global Alliance for Women’s Brain Health Luncheon at the Alzheimer’s Association International Conference in Toronto on July 26, 2016. More than 1,000 caregivers were recruited for Phase I of the study, which documented cognitive impairment in the informal caregiver population compared with matched controls. An informal caregiver is defined as an unpaid person without formal training, such as a family member, who provides care for an individual with dementia. “Given the results we found in Phase I, we have set two goals for Phase II. The first is to look at caregiver stressors that could be possible causes for this cognitive impairment as well as provide an intervention that could help these caregivers with their mental health,” said Dr. Cori Lathan, board chair and CEO of AnthroTronix. “The rigor of science can help us better understand and improve caregivers’ health,” said BrightFocus President and CEO Stacy Pagos Haller. “BrightFocus is honored to support such innovative research.” In Phase II, an international cohort of caregivers will use DANATM, AnthroTronix’s FDA-cleared brain health assessment mobile app, to assess their cognitive function over 12 weeks. DANA provides detailed feedback about brain function that can be analyzed for changes over time. All participants in Phase II will use DANA, with some participants also using Mindoula. DANA will track...

AnthroTronix CEO to Conduct Davos Brain Challenge and Discuss Technology and the Brain at the Annual Meeting of the New Champions

WHO:   AnthroTronix (@AnthroTronix), a leader in digital health technology and engineering research and development committed to optimizing the interaction between people and technology. WHAT: At the World Economic Forum’s Annual Meeting of the New Champions, AnthroTronix CEO Dr. Cori Lathan (@clathan) will conduct the Davos Brain Challenge using its FDA-cleared DANA brain health assessment app. AnthroTronix held a similar exhibit at the World Economic Forum Annual Meeting in Davos-Klosters, Switzerland, earlier this year. AnthroTronix will invite attendees to assess their brain health and discover how innovative digital capabilities are transforming the way we assess and monitor our brain health. In addition, Dr. Lathan will discuss how digital technology, such as DANA, is improving our understanding of the brain and how we identify conditions and changes in cognitive function. Dr. Lathan has been named a Technology Pioneer and Young Global Leader by the World Economic Forum and is currently chair of their Global Agenda Council on Artificial Intelligence (AI) and Robotics. WHERE: Davos Brain Challenge Brain Hub, Works in Progress Exhibition Meijiang Convention & Exhibition Centre Tianjin, People’s Republic of China WHEN: June 26 – 28, 2016 Download PDF of press...

AnthroTronix and Cambridge Cognition have signed a distribution agreement to sell DANA, AnthroTronix’s FDA-cleared mobile brain health assessment app, to markets in the U.S. and Europe.

AnthroTronix and Cambridge Cognition Announce Distribution Agreement for Mobile Medical App Silver Spring, Md. – AnthroTronix and Cambridge Cognition Holdings PLC (Cambridge, UK – LSE: COG), have signed a distribution agreement to sell DANATM, AnthroTronix’s FDA-cleared mobile brain health assessment app, to markets in the U.S. and Europe. In the U.S., Cambridge Cognition will distribute DANA for use in academic research, clinical trials, and pharmaceutical development. In the United Kingdom and portions of Europe, DANA will be marketed for use in militaries, academic research, clinical trials, pharmaceutical development, and occupational health screenings. DANA, which was initially developed for use by the U.S. military to help evaluate the medical status of deployed service members, is a mobile medical app that administers game-like tests to assess a person’s brain/cognitive health within minutes. The app can help track cognitive function over time and during treatment for such conditions as depression, dementia/Alzheimer’s Disease, and Post-Traumatic Stress Disorder. DANA can be used on a phone or tablet and works on both the Android and iOS operating systems. “Brain health assessment is a fundamental part of an integrated approach to health care,” said Dr. Cori Lathan, @clathan, founder and CEO of AnthroTronix. “With this agreement, DANA has expanded its global reach and further establishes AnthroTronix as a leader in the growing brain and cognitive health assessment and training market, which is expected to surpass $6 billion worldwide by 2020.” “Having worked informally with AnthroTronix since 2015 we are confident that DANA fits within our existing point-of-care product portfolio and are excited by the opportunity to commercialize the product through established Cambridge Cognition sales channels to...

AnthroTronix and Pelion Healthcare Group Announce Joint Venture to Bring Brain Vital Products to European Market

AnthroTronix and Pelion Healthcare Group Announce Joint Venture to Bring Brain Vital Products to European Market ****** Mobile Tool to Monitor and Evaluate Brain Health Will Now be Available for Consumers and Health Care Professionals Silver Spring, Md. and Łódź, Poland – AnthroTronix and Pelion Healthcare Group have signed a joint venture agreement forming a new company, DANA Brain Vital Europe LTD, with each owning half of the newly established company. The new venture is responsible for developing products based on the DANA platform and distributing them in European markets. Products will be marketed using the “CogniNET” brand within Pelion. DANA, which received FDA clearance in October 2014, is a mobile medical app that can be used on a phone or tablet and works on both the Android and iOS operating systems. DANA administers game-like tests that can provide data within minutes to help assess and measure a person’s brain/cognitive health. The app can help clinicians track cognitive function during treatment for such conditions as depression, dementia/Alzheimer’s Disease, and Post-Traumatic Stress Disorder (PTSD). “We are excited to partner with Pelion to bring DANA not just to health care professionals but also to consumers in Europe,” said Dr. Cori Lathan, @clathan, founder and CEO of AnthroTronix. “Along with tracking and evaluation done by medical professionals, individuals now will be able to track their brain health over time, allowing them to identify patterns in their own cognitive efficiency.” “It is exciting that we can combine 26 years of Pelion’s experience in the healthcare sector and the latest achievements in the area of science represented by AnthroTronix, with the expectations of patients,” said...